PARP1 and familial pancreatic carcinoma: Currently, PARP inhibitors are being evaluated in clinical trials in other cancer settings such as nonsmall cell lung cancer, pancreatic cancer, and gastric cancer (ClinicalTrials.gov Identifiers NCT01082549, NCT02184195, NCT03427814, respectively).